Mallinckrodt Recognizes First Hepatorenal Syndrome (HRS) Awareness Day

October 14, 2025 at 07:00 AM EST - Mallinckrodt plc, a global specialty pharmaceutical company, today announced that the Company supports the inaugural Hepatorenal Syndrome (HRS) Awareness Day, established by the American Liver Foundation (ALF). HRS Awareness Day will be observed on October 14 during National Liver Awareness Month. The purpose of this initiative is to promote increased awareness and education regarding HRS, including potential complications, the importance of early detection and treatment, and to honor the stories of HRS patients and their experiences.

HRS is classified into two distinct types – a rapidly progressive type that leads to renal failure where patients are typically hospitalized for their care (HRS-acute kidney injury (AKI)) and a more chronic type that progresses slowly over weeks to months (HRS-chronic kidney disease (CKD)).1,2 HRS is estimated to affect more than 60,000 Americans annually, approximately 0.01% of the U.S. population,3 making it a rare condition; and rates of HRS hospitalizations are increasing.4

"We're proud to support this moment for the HRS community and help to raise visibility of this condition and the patients, care teams, and healthcare professionals it impacts," said Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer, Mallinckrodt. "U.S. physicians historically have faced significant challenges treating patients with HRS."

"HRS is a life-threatening complication of liver disease,1 so it is fitting to elevate knowledge about this condition and recognize those affected by it during National Liver Awareness Month," said Lorraine Stiehl, CEO, American Liver Foundation. "Thank you to our sponsors, including Mallinckrodt, who have made this awareness day possible and are committed to bringing treatment options to patients in need."